Home  »  Company   »  Why Should You Add Intercept Pharmaceuticals Inc. ...

Why Should You Add Intercept Pharmaceuticals Inc. (ICPT) To Your Portfolio?

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has a beta value of 1.12 and has seen 1.55 million shares traded in the last trading session. The company, currently valued at $733.33M, closed the last trade at $17.86 per share which meant it gained $0.7 on the day or 4.08% during that session. The ICPT stock price is -18.98% off its 52-week high price of $21.25 and 39.47% above the 52-week low of $10.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.82 million shares traded. The 3-month trading volume is 905.04K shares.

The consensus among analysts is that Intercept Pharmaceuticals Inc. (ICPT) is a Hold stock at the moment, with a recommendation rating of 2.70. 1 analysts rate the stock as a Sell, while 2 rate it as Overweight. 9 out of 16 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is $5.56.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) trade information

Sporting 4.08% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 09/20/22 when the ICPT stock price touched $17.86 or saw a rise of 6.98%. Year-to-date, Intercept Pharmaceuticals Inc. shares have moved 9.64%, while the 5-day performance has seen it change 6.18%. Over the past 30 days, the shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) have changed 0.68%. Short interest in the company has seen 5.49 million shares shorted with days to cover at 4.52.

Wall Street analysts have a consensus price target for the stock at $26.33, which means that the shares’ value could jump 32.17% from current levels. The projected low price target is $10.00 while the price target rests at a high of $82.00. In that case, then, we find that the current price level is -359.13% off the targeted high while a plunge would see the stock lose 44.01% from current levels.

Intercept Pharmaceuticals Inc. (ICPT) estimates and forecasts

Figures show that Intercept Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 8.51% over the past 6 months, with this year growth rate of -1.74%, compared to 1.40% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 5,154.50% and 34.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -5.10%.

16 analysts offering their estimates for the company have set an average revenue estimate of $98.81 million for the current quarter. 16 have an estimated revenue figure of $75.95 million for the next quarter concluding in Dec 2022. Year-ago sales stood $92.83 million and $92.4 million respectively for this quarter and the next, and analysts expect sales will grow by 6.40% for the current quarter and -17.80% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.70% over the past 5 years. Earnings growth for 2022 is a modest 65.60% while over the next 5 years, the company’s earnings are expected to decrease by -8.89%.

ICPT Dividends

Intercept Pharmaceuticals Inc. is expected to release its next earnings report between November 01 and November 07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s Major holders

Insiders own 3.31% of the company shares, while shares held by institutions stand at 73.03% with a share float percentage of 75.53%. Investors are also buoyed by the number of investors in a company, with Intercept Pharmaceuticals Inc. having a total of 231 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 3.48 million shares worth more than $62.09 million. As of Jun 29, 2022, State Street Corporation held 11.67% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 2.72 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $48.55 million and represent 9.12% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund. As of Aug 30, 2022, the former fund manager holds about 9.24% shares in the company for having 2.75 million shares of worth $49.18 million while later fund manager owns 0.8 million shares of worth $14.29 million as of Jun 29, 2022, which makes it owner of about 2.68% of company’s outstanding stock.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]